Literature DB >> 6300245

Viral inhibition of lymphocyte mitogenesis: interference with the synthesis of functionally active T cell growth factor (TCGF) activity and reversal of inhibition by the addition of same.

M A Wainberg, S Vydelingum, R G Margolese.   

Abstract

We have investigated the mechanisms whereby co-incubation of several types of virus particles with human lymphoid cells in the presence of T cell lectins leads to inhibition of the proliferative response that otherwise ensues. The data indicate that, in the absence of infection, such inhibition can be reversed by the addition to cultures of relatively high concentrations of fluids rich in T cell growth factor (TCGF) activity. The ability of these fluids to achieve such reversal of inhibition is both concentration- and time-dependent. Addition of the factor to virus co-incubated cells more than 26 hr after culture initiation does not restore responsiveness. We have also shown that virus co-incubated cultures are deficient with respect to their ability to synthesize detectable levels of TCGF activity in the presence of phytohemagglutinin. In contrast, the use of relatively dilute virus preparations (less than 10 particles per cell) permits partial responsiveness to lectin as well as the synthesis of moderate levels of TCGF. These finding suggest that viral inhibition of lymphocyte mitogenesis is mediated directly or indirectly by interference with the synthesis of functionally active TCGF activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300245

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Mechanisms of virus-induced immune suppression.

Authors:  M A Wainberg; E L Mills
Journal:  Can Med Assoc J       Date:  1985-06-01       Impact factor: 8.262

2.  Infection of human peripheral blood mononuclear cells with a temperature-sensitive mutant of measles virus.

Authors:  S Vydelingum; J Ilonen; R Salonen; R Marusyk; A Salmi
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

Review 3.  Interactions of viruses with the immune system.

Authors:  C A Mims
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

4.  Reversible interference with TCGF activity by virus particles.

Authors:  M A Wainberg; S Vydelingum; M Boushira; J Legacé-Simard; R G Margolese; B Spira; J Mendelson
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

5.  Inhibition by human T-lymphotropic virus (HTLV-I) of T-lymphocyte mitogenesis: failure of exogenous T-cell growth factor to restore responsiveness to lectin.

Authors:  M A Wainberg; B Spira; M Boushira; R G Margolese
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

6.  Effects of interleukin 2 and large envelope glycoprotein (gp 120) of human immunodeficiency virus (HIV) on lymphocyte proliferative responses to cytomegalovirus.

Authors:  J Krowka; D Stites; J Mills; H Hollander; T McHugh; M Busch; L Wilhelm; L Blackwood
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

7.  Infection of human thymic epithelial cells by human cytomegalovirus and other viruses: effect on secretion of interleukin 1-like activity.

Authors:  M A Wainberg; K Numazaki; L Destephano; I Wong; H Goldman
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

8.  The immunosuppressive effects of measles virus on T cell function--failure to affect IL-2 release or cytotoxic T cell activity in vitro.

Authors:  L K Borysiewicz; P Casali; B Rogers; S Morris; J G Sissons
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

9.  Molecular cloning of a functional bovine interleukin 2 cDNA.

Authors:  R Reeves; A G Spies; M S Nissen; C D Buck; A D Weinberg; P J Barr; N S Magnuson; J A Magnuson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

10.  Enhanced viral inhibition of lymphocyte mitogenesis in patients with advanced breast cancer.

Authors:  R G Margolese; M A Wainberg
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.